These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17486110)

  • 21. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
    Polascik TJ
    Prostate Cancer Prostatic Dis; 2008; 11(1):13-9. PubMed ID: 17923854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
    Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Turner D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(2):198-203. PubMed ID: 18852703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GU radiation oncologists consensus on bone loss from androgen deprivation.
    Duncan GG; Corbett T; Lukka H; Warde P; Pickles T
    Can J Urol; 2006 Feb; 13(1):2962-6. PubMed ID: 16515750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of side effects of androgen deprivation therapy.
    Grossmann M; Zajac JD
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):655-71, x. PubMed ID: 21889727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study.
    Bourke L; Doll H; Crank H; Daley A; Rosario D; Saxton JM
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):647-57. PubMed ID: 21335510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure.
    Bolam KA; Galvão DA; Spry N; Newton RU; Taaffe DR
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):329-38. PubMed ID: 22733158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moderators of resistance-based exercise programs' effect on sarcopenia-related measures in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis.
    Lopez P; Newton RU; Taaffe DR; Winters-Stone K; Galvão DA; Buffart LM
    J Geriatr Oncol; 2023 Jun; 14(5):101535. PubMed ID: 37229882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
    Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
    Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
    Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.